Commonwealth Equity Services LLC Acquires 122,701 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Commonwealth Equity Services LLC raised its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 75.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 285,736 shares of the company’s stock after buying an additional 122,701 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Teva Pharmaceutical Industries were worth $5,772,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. AQR Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 24.6% in the first quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock worth $368,000 after acquiring an additional 4,732 shares during the last quarter. Focus Partners Wealth boosted its holdings in Teva Pharmaceutical Industries by 4.5% in the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock valued at $616,000 after purchasing an additional 1,739 shares during the period. Gateway Investment Advisers LLC boosted its holdings in Teva Pharmaceutical Industries by 123.8% in the 2nd quarter. Gateway Investment Advisers LLC now owns 109,024 shares of the company’s stock valued at $1,827,000 after purchasing an additional 60,308 shares during the period. Swedbank AB grew its position in Teva Pharmaceutical Industries by 1.1% in the 2nd quarter. Swedbank AB now owns 110,653 shares of the company’s stock worth $1,855,000 after purchasing an additional 1,244 shares during the last quarter. Finally, IFM Investors Pty Ltd increased its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the 2nd quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company’s stock worth $3,797,000 after purchasing an additional 19,447 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 200,000 shares of Teva Pharmaceutical Industries stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total transaction of $4,822,000.00. Following the completion of the transaction, the director directly owned 495,000 shares of the company’s stock, valued at approximately $11,934,450. This trade represents a 28.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the completion of the sale, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 622,060 shares of company stock valued at $17,076,965. 0.49% of the stock is owned by insiders.

Teva Pharmaceutical Industries Trading Up 0.4%

TEVA stock opened at $32.62 on Thursday. Teva Pharmaceutical Industries Ltd. has a 1-year low of $12.47 and a 1-year high of $33.42. The firm has a market cap of $37.41 billion, a P/E ratio of 54.36, a P/E/G ratio of 1.86 and a beta of 0.66. The business’s 50 day moving average is $28.68 and its 200-day moving average is $21.90. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. UBS Group raised their price objective on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Scotiabank started coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 price objective on the stock. Finally, The Goldman Sachs Group boosted their price objective on Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $33.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.